Actinium Pharmaceuticals

Founded in New York, Actinium Pharmaceuticals focuses on developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Their core mission is to address unmet medical needs through their pipeline of Antibody Radiation Conjugates (ARCs), which are designed for targeted conditioning and combination therapies. Key products include Iomab-B, which has shown positive top-line results in the pivotal Phase SIERRA trial, and Actimab-A, a CD33 targeting therapeutic for relapsed/refractory acute myeloid leukemia (AML).

Notable affiliated individuals include key researchers and industry experts in oncology and radiotherapy. The company has attracted significant investment from healthcare-focused venture capital firms. Actinium's key achievements include the successful completion of critical clinical trials and the development of a robust pipeline of targeted therapies. Their work has had a substantial impact on advancing cancer treatment options, particularly for patients with limited alternatives.